Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,932 recruiting studies in this area right now.
By phase
- Not applicable2,031
- Phase 21,075
- Phase 1791
- Phase 1/Phase 2481
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma179
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Lymphedema49
- Acute Myeloid Leukemia (AML)48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California397
- Texas185
- Alabama157
- Maryland152
- Arizona127
- Massachusetts105
- Florida104
- New York98
- Ohio72
- Minnesota69
Recruiting studies4,932 total
- NCT06321198Recruiting
Modified stem cells for severe graft-versus-host disease
This trial tests a new type of stem cell therapy (iMSC) for people with steroid-resistant acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. The goal is to see if it's safe and might help control the disease.
Hefei, AnhuiAges 4–70 - NCT06319456RecruitingPhase 3
Study of lisaftoclax plus acalabrutinib for untreated CLL/SLL
This trial tests a new combination of two targeted drugs (lisaftoclax and acalabrutinib) against standard chemo-immunotherapy for people newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma who need treatment. It aims to see if the combination works better.
Bengbu, AnhuiAges 18 years+ - NCT06328764Enrolling by invitationEarly Phase 1
CS-101 for patients with beta-thalassemia
This trial tests a new treatment called CS-101 for people with beta-thalassemia who need regular blood transfusions. It aims to see if CS-101 can help reduce transfusion needs.
Nanning, GuangxiAges 6–35 - NCT05794958RecruitingPhase 1
Safety of second CAR-T re-infusion for hard-to-treat lymphoma
This Phase 1 study tests whether a second re-infusion of axicabtagene ciloleucel (CAR-T) is safe in people with aggressive B-cell non-Hodgkin lymphoma that came back or did not respond after standard second-line CAR-T. It may help some patients by trying to improve disease control while carefully monitoring side effects.
Palo Alto, CaliforniaAges 18 years+ - NCT06327490RecruitingPhase 2
ICG-guided vs. traditional lymphatic drainage for breast cancer surgery
This trial compares a new imaging method (ICG) to the standard method for manual lymphatic drainage during breast cancer surgery. It aims to reduce swelling in the arm after lymph node removal.
Gainesville, FloridaAges 18–99 - NCT06323044Recruiting
Support program for parents giving daily leukemia medicine
This study tests a support program that helps parents give their child's daily leukemia medicine (6-MP) on schedule and overcome any barriers. It aims to make it easier for families to stick with treatment.
Buffalo, New YorkAges Any age - NCT06318143Recruiting
Increasing use of hydroxyurea for sickle cell in Nigeria
This study aims to help more people with sickle cell disease in Nigeria start taking hydroxyurea, a medicine that can prevent pain crises and other complications. It will work with clinics to make it easier for patients to get and stay on this treatment.
AbujaAges 1 year+ - NCT06325280Recruiting
Exercise MRI for Kids with Heart Conditions
This study uses an MRI while exercising to check heart and lung fitness in children with heart disease. It helps doctors learn more about how to care for kids who have had a heart transplant or were born with heart problems.
Edmonton, AlbertaAges 10–18 - NCT06326008RecruitingPhase 1
Donor immune cell therapy for leukemia that returned after treatment
This trial tests a two-step approach using donor immune cells to treat children with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. First, a donor's CD19-targeted cells are given to bridge to a stem cell transplant, followed by CD22-targeted cells to prevent relapse.
Beijing, Beijing MunicipalityAges 1–18 - NCT06327685RecruitingPhase 1
Avapritinib and Decitabine for SM-AHN
This trial tests a combination of two drugs, avapritinib and decitabine, for people with systemic mastocytosis plus another blood cancer (SM-AHN). The goal is to see if the combination works better than either drug alone.
Phoenix, ArizonaAges 18 years+ - NCT06333262RecruitingPhase 2
Fixed-duration pirtobrutinib and obinutuzumab for untreated CLL
This trial tests a combination of two drugs, pirtobrutinib (a pill) and obinutuzumab (an infusion), given for a set period of time in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had any previous treatment for their disease. The goal is to see if this combination can control the cancer effectively.
Scarborough, MaineAges 18 years+ - NCT06319430Recruiting
Play study for kids with physical disabilities
This study looks at how children with physical disabilities play using technology. It may help understand their play patterns and needs.
Winnipeg, ManitobaAges 3–9 - NCT06326463RecruitingPhase 1
CAR T-cell therapy for CD70-positive blood cancers in children
This trial tests a special immune cell therapy (CAR T-cells) that targets a protein called CD70 on blood cancer cells. It is for children and young adults up to age 21 whose cancer has come back or hasn't gotten better with other treatments.
Memphis, TennesseeAges Up to 21 years - NCT06328127Recruiting
Positive psychology program for stem cell transplant survivors
This study tests a positive psychology program—simple exercises to help you feel better emotionally—for people who are about 3 months past a donor stem cell transplant. It's done over the phone, so you can join from home.
Tampa, FloridaAges 18 years+ - NCT06326021RecruitingPhase 1
CD33 CAR T for relapsed or refractory AML
This trial tests a new type of immune therapy called CAR T cells that target the CD33 protein on leukemia cells. It is for people with AML that has returned or not gone away after standard treatments, and who have a stem cell donor available for a transplant afterward.
Shanghai, Shanghai MunicipalityAges 1–70 - NCT06327100RecruitingPhase 1/Phase 2
Tasquinimod for myelofibrosis after JAK inhibitor failure
This trial tests a new drug called tasquinimod, either alone or combined with ruxolitinib, for people with myelofibrosis. It's for patients who haven't gotten enough help from standard treatments or who can't take them.
Houston, TexasAges 18 years+ - NCT05693909RecruitingPhase 2
SP-420 for iron overload in certain blood disorders
This Phase 2 study tests SP-420 to help people with transfusion-related iron overload from either beta-thalassemia or low-risk myelodysplastic syndromes. It aims to see if the treatment can improve how the body handles excess iron, which builds up after repeated transfusions.
CopenhagenAges 18 years+ - NCT06317649RecruitingPhase 2
Venetoclax with hypomethylating agents for older or unfit adults with FLT3-mutated AML
This trial tests a combination of medicines (venetoclax and a hypomethylating agent) for people with acute myeloid leukemia (AML) who have a FLT3 mutation. It may be an option for older adults or those who cannot tolerate intensive chemotherapy.
Birmingham, AlabamaAges 18 years+ - NCT06313398RecruitingEarly Phase 1
Measuring red blood cell lifespan in sickle cell disease
This study uses a harmless vitamin (biotin) to label your red blood cells and track how long they survive. It aims to understand how different blood disorders affect red blood cell lifespan, which may help improve treatments.
Bethesda, MarylandAges 18–100 - NCT06297161Recruiting
A study of Bosulif for chronic myeloid leukemia
This study watches how well the medicine Bosulif works for adults with chronic myeloid leukemia in everyday medical practice. You can join if you’re already taking Bosulif or starting it soon, as long as you started within the last year.
New York, New YorkAges 20 years+ - NCT06312644Recruiting
Study of Ultomiris safety during pregnancy
This study looks at the safety of the medication Ultomiris when taken during pregnancy or breastfeeding. If you are pregnant and currently taking Ultomiris for an approved condition, this research will help gather information on how it affects you and your baby.
Boston, MassachusettsAges Any age - NCT06299540Recruiting
Physical activity program for CLL patients on ibrutinib
This study tests whether a personalized physical activity program can improve quality of life for people with CLL who are starting the drug ibrutinib. You would wear an activity watch and use a digital tool to track your activity over time.
ToulouseAges 18 years+ - NCT06298630Recruiting
Long-term study of BRL-101 for transfusion-dependent beta-thalassemia
This study follows patients who have already been treated with BRL-101 for transfusion-dependent beta-thalassemia. Its goal is to track long-term outcomes and safety.
Guangzhou, GuangdongAges 3–35 - NCT06304103RecruitingPhase 2
Study of AND017 for low-risk myelodysplastic syndrome
This trial tests an experimental drug called AND017 for people with a certain type of myelodysplastic syndrome (MDS) that is low-risk and not linked to a chromosome 5 deletion. The goal is to see if AND017 can help improve low red blood cell counts (anemia) and reduce or avoid the need for blood transfusions.
Hangzhou, ZhejiangAges 18–75
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,932 recruiting hematology studies from the U.S. registry right now, out of 7,384 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.